Top

Journal of Clinical Immunology

Published in:

Open Access 02-02-2023 | Immunodeficiency | Original Article

Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD)

Authors: Yan Li, Mengyue Deng, Tongxin Han, Wenxiu Mo, Huawei Mao

Published in: Journal of Clinical Immunology | Issue 4/2023

Abstract

Purpose

Sideroblastic anemia, immunodeficiency, periodic fevers, and developmental delay (SIFD) is an autosomal recessive syndrome caused by biallelic loss-of-function variant of tRNA nucleotidyl transferase 1 (TRNT1). Efficacious methods to treat SIFD are lacking. We identified two novel mutations in TRNT1 and an efficacious and novel therapy for SIFD.

Methods

We retrospectively summarized the clinical records of two patients with SIFD from different families and reviewed all published cases of SIFD.

Results

Both patients had periodic fever, developmental delay, rash, microcytic anemia, and B cell lymphopenia with infections. Whole-exome sequencing of patient 1 identified a previously unreported homozygous mutation of TRNT1 (c.706G > A/p.Glu236Lys). He received intravenous immunoglobulin (IVIG) replacement and antibiotics, but died at 1 year of age. Gene testing in patient 2 revealed compound heterozygous mutations (c.907C > G/p.Gln303Glu and c.88A > G/p.Met30Val) in TRNT1, the former of which is a novel mutation. Periodic fever was controlled in the first month after adalimumab therapy and IVIG replacement, but recurred in the second month. Adalimumab was discontinued and replaced with thalidomide, which controlled the periodic fever and normalized inflammatory markers effectively. A retrospective analysis of reported cases revealed 69 patients with SIFD carrying 46 mutations. The male: female ratio was 1: 1, and the mean age of onset was 3.0 months. The most common clinical manifestations in patients with SIFD were microcytic anemia (82.6%), hypogammaglobulinemia/B cell lymphopenia (75.4%), periodic fever (66.7%), and developmental delay (60.0%). In addition to the typical tetralogy, SIFD features several heterogeneous symptoms involving multiple systems. Corticosteroids, immunosuppressants, and anakinra have low efficacy, whereas etanercept suppressed fever and improved anemia in reports. Bone-marrow transplantation can be used to treat severe SIFD, but carries a high risk. In total, 28.2% (20/71) of reported patients died, mainly because of multi-organ failure. Biallelic mutations located in exon1-intron5 lead to more severe phenotypes and higher mortality. Furthermore, 15.5% (11/71) patients survived to adulthood. The symptoms could be resolved spontaneously in five patients.

Conclusions

Thalidomide can control the inflammation of SIFD and represents a new treatment for SIFD.

Available only for authorised users

Slade A, Kattini R, Campbell C, Holcik M. Diseases associated with defects in tRNA CCA Addition. Int J Mol Sci. 2020;21(11). https://doi.org/10.3390/ijms21113780.

Hou YM. CCA addition to tRNA: implications for tRNA quality control. IUBMB Life. 2010;62(4):251–60. https://doi.org/10.1002/iub.301.CrossRefPubMedPubMedCentral

Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM, et al. A novel syndrome of congenital sideroblastic anemia, B cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood. 2013;122(1):112–23. https://doi.org/10.1182/blood-2012-08-439083.CrossRefPubMedPubMedCentral

Bardou MLD, Rivitti-Machado MC, Michalany NS, de Jesus AA, Goldbach-Mansky R, Barros JCR, et al. Neutrophilic dermatosis: a new skin manifestation and novel pathogenic variant in a rare autoinflammatory disease. Australas J Dermatol. 2021;62(2):e276–9. https://doi.org/10.1111/ajd.13527.CrossRefPubMed

Chakraborty PK, Schmitz-Abe K, Kennedy EK, Mamady H, Naas T, Durie D, et al. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood. 2014;124(18):2867–71. https://doi.org/10.1182/blood-2014-08-591370.CrossRefPubMedPubMedCentral

Orlando F, Naddei R, Stellacci E, Gallinoro CM, Melis D, Tartaglia M, et al. Etanercept as a successful therapy in autoinflammatory syndrome related to TRNT1 mutations: a case-based review. Clin Rheumatol. 2021;40(10):4341–8. https://doi.org/10.1007/s10067-021-05653-3.CrossRefPubMed

Mendonca LO, Prado AI, Costa IMC, Bandeira M, Dyer R, Barros SF, et al. Case report: expanding clinical, immunological and genetic findings in sideroblastic anemia with immunodeficiency, fevers and development delay (SIFD) syndrome. Front Immunol. 2021;12:586320. https://doi.org/10.3389/fimmu.2021.586320.CrossRefPubMedPubMedCentral

Giannelou A, Wang H, Zhou Q, Park YH, Abu-Asab MS, Ylaya K, et al. Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors. Ann Rheum Dis. 2018;77(4):612–9. https://doi.org/10.1136/annrheumdis-2017-212401.CrossRefPubMed

Sestan M, Arsov T, Kifer N, Frkovic M, Vinuesa CG, Jelusic M. Periodic fever syndrome with novel TRNT1 variant-possible cause of TRNT1 deficiency or just an incidental finding? 10th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID). Pediatr Rheumatol. 2019;17:18. https://doi.org/10.1186/s12969-019-0313-x.CrossRef

10.

Kisla Ekinci RM, Zararsiz A, Demir GU, Anlas O. A rare autoinflammatory disorder in a pediatric patient with favorable response to etanercept: sideroblastic anemia with B cell immunodeficiency, periodic fevers, and developmental delay syndrome. Pediatr Allergy Immunol Pulmonol. 2022;35(3):129–32. https://doi.org/10.1089/ped.2022.0090.CrossRefPubMed

11.

Maccora I, Ramanan AV, Vergnano S, Roderick MR. Sideroblastic anaemia, immunodeficiency, periodic fevers and developmental delay (SIFD) presenting as systemic inflammation with arthritis. Rheumatology (Oxford). 2021;60(7):e234–6. https://doi.org/10.1093/rheumatology/keab010.CrossRefPubMed

12.

Wedatilake Y, Niazi R, Fassone E, Powell CA, Pearce S, Plagnol V, et al. TRNT1 deficiency: clinical, biochemical and molecular genetic features. Orphanet J Rare Dis. 2016;11(1):90. https://doi.org/10.1186/s13023-016-0477-0.CrossRefPubMedPubMedCentral

13.

Barton C, Kausar S, Kerr D, Bitetti S, Wynn R. SIFD as a novel cause of severe fetal hydrops and neonatal anaemia with iron loading and marked extramedullary haemopoiesis. J Clin Pathol. 2018;71(3):275–8. https://doi.org/10.1136/jclinpath-2017-204698.CrossRefPubMed

14.

Odom J, Amin H, Gijavanekar C, Elsea SH, Kralik S, Chinen J, et al. A phenotypic expansion of TRNT1 associated sideroblastic anemia with immunodeficiency, fevers, and developmental delay. Am J Med Genet A. 2022;188(1):259–68. https://doi.org/10.1002/ajmg.a.62482.CrossRefPubMed

15.

Rigante D, Stellacci E, Leoni C, Onesimo R, Radio FC, Pizzi S, et al. Biallelic TRNT1 variants in a child with B cell immunodeficiency, periodic fever and developmental delay without sideroblastic anemia (SIFD variant). Immunol Lett. 2020;225:64–5. https://doi.org/10.1016/j.imlet.2020.06.012.CrossRefPubMed

16.

Wang J, Deng Q, He X, Chen D, Hang S, Gao Y, et al. Two cases of sideroblastic anemia with B cell immunodeficiency, periodic fevers, and developmental delay (SIFD) syndrome in Chinese Han children caused by novel compound heterozygous variants of the TRNT1 gene. Clin Chim Acta. 2021;521:244–50. https://doi.org/10.1016/j.cca.2021.07.019.CrossRefPubMed

17.

Yang L, Xue X, Zeng T, Chen X, Zhao Q, Tang X, et al. Novel biallelic TRNT1 mutations lead to atypical SIFD and multiple immune defects. Genes Dis. 2020;7(1):128–37. https://doi.org/10.1016/j.gendis.2020.01.005.CrossRefPubMedPubMedCentral

18.

Jfri A, El-Helou T, Watters KA, Belisle A, Litvinov IV, Netchiporouk E. Congenital sideroblastic anemia associated with B cell immunodeficiency, periodic fevers, and developmental delay: a case report and review of mucocutaneous features. SAGE Open Med Case Rep. 2019;7:2050313X19876710. https://doi.org/10.1177/2050313X19876710.CrossRefPubMedPubMedCentral

19.

DeLuca AP, Whitmore SS, Barnes J, Sharma TP, Westfall TA, Scott CA, et al. Hypomorphic mutations in TRNT1 cause retinitis pigmentosa with erythrocytic microcytosis. Hum Mol Genet. 2016;25(1):44–56. https://doi.org/10.1093/hmg/ddv446.CrossRefPubMed

20.

Hull S, Malik AN, Arno G, Mackay DS, Plagnol V, Michaelides M, et al. Expanding the phenotype of TRNT1-related immunodeficiency to include childhood cataract and inner retinal dysfunction. JAMA Ophthalmol. 2016;134(9):1049–53. https://doi.org/10.1001/jamaophthalmol.2015.5833.CrossRefPubMed

21.

Topyildiz E, Edeer Karaca N, Bas I, Aykut A, Durmaz A, Guven Bilgin RB, et al. A Novel homozygous TRNT1 mutation in a child with an early diagnosis of common variable immunodeficiency leading to mild hypogammaglobulinemia and hemolytic anemia. J Pediatr Hematol Oncol. 2021;43(6):e780–4. https://doi.org/10.1097/MPH.0000000000002101.CrossRefPubMed

22.

Kumaki E, Tanaka K, Imai K, Aoki-Nogami Y, Ishiguro A, Okada S, et al. Atypical SIFD with novel TRNT1 mutations: a case study on the pathogenesis of B cell deficiency. Int J Hematol. 2019;109(4):382–9. https://doi.org/10.1007/s12185-019-02614-0.CrossRefPubMed

23.

Bader-Meunier B, Rieux-Laucat F, Touzot F, Fremond ML, Andre-Schmutz I, Fraitag S, et al. Inherited immunodeficiency: a new association with early-onset childhood panniculitis. Pediatrics. 2018;141(Suppl 5):S496–500. https://doi.org/10.1542/peds.2017-0213.CrossRefPubMed

24.

Sasarman F, Thiffault I, Weraarpachai W, Salomon S, Maftei C, Gauthier J, et al. The 3’ addition of CCA to mitochondrial tRNASer(AGY) is specifically impaired in patients with mutations in the tRNA nucleotidyl transferase TRNT1. Hum Mol Genet. 2015;24(10):2841–7. https://doi.org/10.1093/hmg/ddv044.CrossRefPubMedPubMedCentral

25.

Frans G, Moens L, Schaballie H, Wuyts G, Liston A, Poesen K, et al. Homozygous N-terminal missense mutation in TRNT1 leads to progressive B cell immunodeficiency in adulthood. J Allergy Clin Immunol. 2017;139(1):360-3 e6. https://doi.org/10.1016/j.jaci.2016.06.050.CrossRefPubMed

26.

Lougaris V, Chou J, Baronio M, Gazzurelli L, Lorenzini T, Soresina A, et al. Novel biallelic TRNT1 mutations resulting in sideroblastic anemia, combined B and T cell defects, hypogammaglobulinemia, recurrent infections, hypertrophic cardiomyopathy and developmental delay. Clin Immunol. 2018;188:20–2. https://doi.org/10.1016/j.clim.2017.11.008.CrossRefPubMed

27.

Fouquet C, Le Rouzic MA, Leblanc T, Fouyssac F, Leverger G, Hessissen L, et al. Genotype/phenotype correlations of childhood-onset congenital sideroblastic anaemia in a European cohort. Br J Haematol. 2019;187(4):530–42. https://doi.org/10.1111/bjh.16100.CrossRefPubMed

28.

Ferraroni NR, De Jesus AA, Goldbach-Mansky R, Barros JCR, Grumach AS. Sideroblastic anemia, immunodeficiency, fever and developmental delay (SIFD) referred as leukemia cutis. 2017 LASID Meeting Abstracts. J Clin Immunol. 2017;37:1–74. https://doi.org/10.1007/s10875-017-0442-2.CrossRef

29.

Foster K, Bergstrom K, Holloman A, Marcogliese A, Yates A. ASPHO ABSTRACTS: congenital sideroblastic anemia, immunodeficiency, periodic fevers, and developmental delay syndrome masquerading as alpha thalassemia variant. Pediatr Blood Cancer. 2018;2018(e2705):S48. https://doi.org/10.1002/pbc.27057.CrossRef

30.

Mariani R, Gong S. Bone marrow histopathologic findings in SIFD syndrome: beyond the erythroid lineage. Blood. 2018;132(13):1459. https://doi.org/10.1182/blood-2018-06-860239.CrossRefPubMed

31.

Fremond ML, Melki I, Kracker S, Bondet V, Duffy D, Rice GI, et al. Comment on: “Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors” by Giannelou et al: mutations in TRNT1 result in a constitutive activation of type I interferon signalling. Ann Rheum Dis. 2019;78(8):e86. https://doi.org/10.1136/annrheumdis-2018-213745.CrossRefPubMed

32.

Eisenberg R, Mehta R, Schneider A, Shliozberg J. P276 homozygous TRNT1 (TRNA nucleotidyl transferase 1) mutation in a patient with pyropoikilocytosis and humoral immunodeficiency. Ann Allergy Asthma Immunol. 2017;119(5):70. https://doi.org/10.1016/j.anai.2017.08.192.CrossRef

33.

Bravo Garcia-Morato M, Padilla-Merlano B, Matas Perez E, Valdivieso Shephard JL, Robles Marhuenda A, Santos Simarro F, et al. Hypomorphic variant in TRNT1 induces a milder autoinflammatory disease with congenital cataracts and impaired sexual development. Rheumatology (Oxford). 2022;61(5):e114–6. https://doi.org/10.1093/rheumatology/keab903.CrossRefPubMed

34.

Hoang TK, Albert DA. Novel presentations of periodic fever syndromes: discrepancies between genetic and clinical diagnoses. Eur J Rheumatol. 2019;6(1):12–8. https://doi.org/10.5152/eurjrheum.2018.18023.CrossRefPubMed

35.

Zhou X, Zhou J, Zhao J. Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report. BMC Infect Dis. 2020;20(1):500. https://doi.org/10.1186/s12879-020-05231-z.CrossRefPubMedPubMedCentral

36.

Gorodetsky C, Morel C, Tein I. P133 Expanding the phenotype of TRNT1 mutations to include Leigh syndrome. Canadian J Neurol Sci J Canadien Des Sci Neurologiques. 2018;45(S2):S51–S51. https://doi.org/10.1017/cjn.2018.235.CrossRef

37.

Giannelou A, Zhou Q, Stoffels M, Ombrello A, Stone D, Edwan JH, et al. A2.35 TRNT1 missense mutations define a new periodic fever syndrome. Ann Rheum Dis. 2015;74:A30. https://doi.org/10.1136/annrheumdis-2015-207259.70.CrossRef

38.

Jin Y, Zhang L, Ning B, Hong H, Xiao W, Tong W, et al. Application of genome analysis strategies in the clinical testing for pediatric diseases. Pediatr Investig. 2018;2(2):72–81. https://doi.org/10.1002/ped4.12044.CrossRefPubMedPubMedCentral

39.

Liwak-Muir U, Mamady H, Naas T, Wylie Q, McBride S, Lines M, et al. Impaired activity of CCA-adding enzyme TRNT1 impacts OXPHOS complexes and cellular respiration in SIFD patient-derived fibroblasts. Orphanet J Rare Dis. 2016;11(1):79. https://doi.org/10.1186/s13023-016-0466-3.CrossRefPubMedPubMedCentral

40.

Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–40. https://doi.org/10.1016/s1471-4906(01)02060-9.CrossRefPubMed

41.

Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363(9423):1802–11. https://doi.org/10.1016/S0140-6736(04)16308-3.CrossRefPubMed

Title: Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD)
Authors: Yan Li
Mengyue Deng
Tongxin Han
Wenxiu Mo
Huawei Mao
Publication date: 02-02-2023
Publisher: Springer US
Keywords: Immunodeficiency
Sideroblastic Anemia
Published in: Journal of Clinical Immunology / Issue 4/2023
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-023-01441-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD)

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2023

Type I Interferonopathy due to a Homozygous Loss-of-Inhibitory Function Mutation in STAT2

The Association of Serum Immunoglobulins with Risk of Cardiovascular Disease and Mortality: the Rotterdam Study

Compound Heterozygous Mutations in PRKCD Associated with Early-Onset Lupus and Severe and Invasive Infections in Siblings

Inborn Errors of Immunity in the Republic of Moldova: Advances and Hope

Clinical Non-penetrance Associated with Biallelic Mutations in the RNase H2 Complex

Immunologic, Molecular, and Clinical Profile of Patients with Chromosome 22q11.2 Duplications

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page